SCHEMBL17487315

SCHEMBL17487315

Nc1ccc2nc(N)n(Cc3ccc(Oc4ccc(Cl)cc4)cc3)c2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 2/20 0.59
CXCL8 P10145 2/20 0.59
NOD1 Q9Y239 2/20 0.59
TNF P01375 1/20 0.59
NOD2 Q9HC29 1/20 0.59
KMT2A Q03164 1/20 0.48
CSF1R P07333 2/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 2/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
POLB P06746 1/20 0.46
HTT P42858 1/20 0.46
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
GRIN1 Q05586 1/20 0.42
GRIN2B Q13224 1/20 0.42
DCTPP1 Q9H773 1/20 0.41
TP53 P04637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17488183 0.89 NOD1 (0.52) SOS1CXCL8NOD1TNFNOD2
SCHEMBL17487426 0.89 CXCL8 (0.50) SOS1CXCL8NOD1TNFNOD2
SCHEMBL17488076 0.88 NOD1 (0.63) SOS1CXCL8NOD1TNFNOD2
SCHEMBL18960382 0.88 SOS1 (0.56) SOS1CXCL8NOD1TNFNOD2
SCHEMBL17487358 0.87 SOS1 (0.48) SOS1CXCL8NOD1TNFNOD2
SCHEMBL17487436 0.87 SOS1 (0.44) SOS1CXCL8NOD1TNFNOD2
SCHEMBL17487438 0.86 CXCL8 (0.44) SOS1CXCL8NOD1TNFNOD2
SCHEMBL17487443 0.85 TYMS (0.47) SOS1CXCL8NOD1TNFNOD2
SCHEMBL17487335 0.84 KDM4E (0.46) SOS1CXCL8NOD1TNFNOD2
SCHEMBL17487437 0.82 CSF1R (0.51) SOS1CXCL8NOD1TNFNOD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2017-06-15 US disclosed
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2017-06-15 US disclosed
WO-2016016421-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2016-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS ALOX5, ALOX15, ALOX12 SOS1 4452/4885CXCL8 834/4885NOD1 2374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.